Cytek Biosciences (NASDAQ:CTKB) Releases Quarterly Earnings Results

Cytek Biosciences (NASDAQ:CTKB) announced its quarterly earnings results on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.07), FiscalAI reports. Cytek Biosciences had a negative return on equity of 9.81% and a negative net margin of 36.25%.The business had revenue of $44.14 million during the quarter, compared to the consensus estimate of $44.23 million.

Here are the key takeaways from Cytek Biosciences’ conference call:

• Q1 revenue was $44.1M (up 6% YoY), led by a strong U.S. rebound with U.S. revenue of $24.4M (up 32%), indicating recovering instrument demand.
• Recurring revenue (reagents + service) reached $18.4M and now represents 35% of trailing 12?month revenue (19% YoY growth); installed base grew by 125 units to 3,789 and the Aurora Evo is driving product traction.
• Profitability worsened—GAAP net loss widened to $18.9M (from $11.4M) and adjusted EBITDA loss was $9.1M, driven by a 13% rise in operating expenses and a $5.6M increase in G&A largely from patent litigation and consulting.
• Management reaffirmed full?year guidance of $205M–$212M (2%–5% growth), holds $262.2M in cash and expects to deliver positive adjusted EBITDA for full year 2026.

Cytek Biosciences Stock Down 6.3%

CTKB traded down $0.31 during trading hours on Friday, hitting $4.61. 1,361,764 shares of the company’s stock were exchanged, compared to its average volume of 600,220. Cytek Biosciences has a 1-year low of $2.37 and a 1-year high of $6.18. The stock’s 50-day moving average is $4.48 and its two-hundred day moving average is $4.75. The stock has a market cap of $595.34 million, a price-to-earnings ratio of -8.09 and a beta of 1.22.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cytek Biosciences in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.38.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CTKB. Boston Partners boosted its holdings in Cytek Biosciences by 13,369.4% during the fourth quarter. Boston Partners now owns 5,008,309 shares of the company’s stock worth $25,297,000 after purchasing an additional 4,971,126 shares during the last quarter. Topline Capital Management LLC boosted its holdings in Cytek Biosciences by 255.7% during the second quarter. Topline Capital Management LLC now owns 5,231,260 shares of the company’s stock worth $17,786,000 after purchasing an additional 3,760,485 shares during the last quarter. Wellington Management Group LLP acquired a new position in Cytek Biosciences during the third quarter worth $8,817,000. Millennium Management LLC boosted its position in Cytek Biosciences by 269.6% during the third quarter. Millennium Management LLC now owns 3,418,382 shares of the company’s stock valued at $11,862,000 after purchasing an additional 2,493,610 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in Cytek Biosciences by 527.6% during the fourth quarter. Russell Investments Group Ltd. now owns 1,001,127 shares of the company’s stock valued at $5,056,000 after purchasing an additional 841,614 shares during the last quarter. Institutional investors and hedge funds own 69.46% of the company’s stock.

Cytek Biosciences Company Profile

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.